Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Genmab, de Deense parel

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Genmab, de Deense parel

145 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 | Laatste | Omlaag ↓
  1. [verwijderd] 8 oktober 2009 19:22

    Glaxo seeks to overturn Genentech antibody patent

    * Glaxo challenges Cabilly antibody drug patent
    * Argues patent invalid, not infringed by Arzerra

    * Glaxo partner Genmab sees no impact on 2009 guidance

    LONDON, Oct 8 (Reuters) - GlaxoSmithKline (GSK.L) has challenged a biotech patent held by Roche's (ROG.VX) Genentech unit in a bid to give a clear run to its experimental cancer and arthritis drug Arzerra, being developed with Genmab (GEN.CO).

    The British drugmaker said on Thursday it had filed a declaratory judgment action at the U.S. District Court for the Southern District of Florida arguing the "Cabilly" patent was invalid, unenforceable and not infringed by Arzerra.

    Genmab, a Danish biotech company whose prospects hinge on the success of Arzerra, said the legal case was not expected to affect its financial guidelines for 2009.

    The patent has been in dispute before.

    In February, the U.S. Patent and Trademark Office confirmed that Genentech's patent was valid, in a reversal of an earlier decision.

    A year earlier, the patent office had rejected the validity of the Cabilly patent, prompting Genentech to appeal. The patent remained in effect during that reexamination process. (Reporting by Ben Hirschler; Editing by Hans Peters)

    www.reuters.com/article/marketsNews/i...
  2. [verwijderd] 8 oktober 2009 19:23
    Declaratory Judgment Action Filed by GSK

    COPENHAGEN, Denmark, Oct. 8, 2009 (GLOBE NEWSWIRE) -- Summary: GSK has today filed a declaratory judgment action seeking a declaration that the US Patent 6,331,415 (the "Cabilly" patent) is invalid, unenforceable and not infringed by Arzerra.

    Genmab A/S (Copenhagen:GEN - News) announced today that in connection with Genmab's collaboration agreement with GSK regarding ofatumumab (Arzerra(TM)) GSK has today filed a declaratory judgment action at the United States District Court for the Southern District of Florida seeking a declaration that U.S. Patent 6,331,415 (the "Cabilly" patent) owned by Genentech, Inc. and City of Hope, is invalid, unenforceable and not infringed by Arzerra. The filing of this action is not expected to affect Genmab's financial guidelines for 2009.

    About Genmab A/S

    Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

    This Stock Exchange Release contains forward-looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward-looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

    Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM); HuMax-TF(TM); HuMax-Her2(TM); HuMax-VEGF(TM) and UniBody(R) are all trademarks of Genmab A/S. Arzerra(TM) is a trademark of GlaxoSmithKline

    finance.yahoo.com/news/Declaratory-Ju...
  3. [verwijderd] 19 april 2010 21:02
    Begin van de ommekeer van het desastreuze koersverloop?

    Genmab Achieves Milestone in Arzerra Collaboration
    Copenhagen, Denmark; April 19, 2010 – Genmab A/S (OMX: GEN) announced today it has reached a milestone for Arzerra™ (ofatumumab) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 87 million (approximately USD 16 million) was triggered by the European Commission’s granting of a conditional marketing authorization for ofatumumab for the treatment of refractory chronic lymphocytic leukemia (CLL).

    “This milestone marks an important achievement; the first Genmab antibody to reach the market in Europe,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

    Ofatumumab is a novel human monoclonal antibody with a unique mode of action. It targets a unique part of the CD20 molecule encompassing an epitope in the small loop. The CD20 molecule is a key target in CLL therapy, because it is expressed in most B cell malignancies.

    ------------

    GlaxoSmithKline Receives Conditional Marketing Authorization in the EU for Arzerra (Ofatumumab)
    Copenhagen, Denmark; April 19, 2010 –GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) confirmed today that the European Commission (EC) has granted a conditional marketing authorization for Arzerra™ (ofatumumab) for the treatment of refractory chronic lymphocytic leukemia (CLL). Ofatumumab is indicated for the treatment of CLL in patients who are refractory (have not responded) to fludarabine and alemtuzumab. Fludarabine and alemtuzumab are standard therapies currently used to treat CLL.
145 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 918,72 -0,64%
EUR/USD 1,0706 0,00%
FTSE 100 8.146,86 -0,21%
Germany40^ 18.004,30 -1,43%
Gold spot 2.332,68 0,00%
NY-Nasdaq Composite 17.688,88 +0,12%

Stijgers

UNILEV...
+0,76%
KPN
+0,75%
DSM FI...
+0,73%
NSI
+0,72%
Vastned
+0,65%

Dalers

EBUSCO...
-6,53%
Avantium
-4,28%
SIGNIF...
-3,78%
ALLFUN...
-3,55%
BESI
-3,52%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!